Three SGLT2 inhibitors have regulatory approval for use in chronic kidney disease: dapagliflozin (Farxiga), empagliflozin (Jardiance), and canagliflozin (Invokana). Dapagliflozin was the first, receiving FDA approval in April 2021 for CKD broadly, while canagliflozin’s kidney-specific approval is limited to diabetic kidney disease. Empagliflozin followed with its own CKD indication after results from the EMPA-KIDNEY trial. The approvals were not interchangeable rubber stamps, though. Each drug was tested in a somewhat different population, received a somewhat different label, and carries different practical considerations for the person taking it.
Dapagliflozin and the DAPA-CKD Breakthrough
Dapagliflozin holds the broadest CKD label of the three. Its approval covers CKD stages 1 through 4 in adults whose estimated glomerular filtration rate (eGFR) is above 25 mL/min/1.73 m² and who have significant proteinuria, regardless of whether they have diabetes.1PMC. Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives That “regardless of diabetes” language was a turning point. Before this, SGLT2 inhibitors were thought of almost exclusively as diabetes drugs that happened to help the kidneys. Dapagliflozin’s approval reframed them as kidney drugs in their own right.
The trial that earned this label, DAPA-CKD, enrolled over 4,300 participants with CKD and albuminuria, about a third of whom did not have type 2 diabetes. Over roughly two and a half years, the primary composite outcome (a sustained drop in kidney function of at least 50%, end-stage kidney disease, or kidney or cardiovascular death) occurred in about 9% of the dapagliflozin group compared with about 15% in the placebo group. The risk of the kidney-specific composite fell by roughly 44%, and all-cause mortality dropped by about 31%.2PubMed. Dapagliflozin in Patients with Chronic Kidney Disease The trial was stopped early because the benefits were so clear that continuing to give some participants a placebo would have been unethical.
A subgroup analysis confirmed the benefit held across different causes of CKD, not just diabetic nephropathy. People with glomerulonephritides (a group of inflammatory kidney diseases) saw a strong effect, and those with ischemic or hypertensive CKD trended in the same direction.3The Lancet Diabetes & Endocrinology. Dapagliflozin in patients with chronic kidney disease: a subgroup analysis of the DAPA-CKD trial The consistency of this effect across kidney disease causes is one of the reasons dapagliflozin has the widest CKD label.
Canagliflozin and Diabetic Kidney Disease
Canagliflozin was actually the first SGLT2 inhibitor to demonstrate a clear kidney benefit in a dedicated trial, CREDENCE, published in 2019. That trial focused specifically on people with type 2 diabetes and established diabetic kidney disease. The primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or kidney or cardiovascular death) was about 30% lower in the canagliflozin group. The risk of end-stage kidney disease alone fell by roughly 32%, and hospitalization for heart failure dropped by about 39%.4PubMed. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Like DAPA-CKD, CREDENCE was also stopped early.
Because CREDENCE enrolled only people with type 2 diabetes, canagliflozin’s kidney-specific approval is narrower: it covers diabetic kidney disease rather than CKD broadly.5PubMed Central. Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for Clinical Practice: A Narrative Review This does not mean canagliflozin would not work in non-diabetic CKD. It means it simply was not tested in that population in a dedicated kidney trial, so the label reflects only what was proven.
One interesting finding from a post hoc analysis of CREDENCE was that early reduction in albuminuria predicted long-term outcomes. Canagliflozin lowered the urine albumin-to-creatinine ratio by about 31% at six months, and each additional 30% drop in that ratio was independently linked to a lower risk of kidney failure and cardiovascular events.6PubMed Central. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial That finding is useful in practice because it gives clinicians an early signal of whether the drug is working for a given patient.
Empagliflozin and the EMPA-KIDNEY Trial
Empagliflozin’s CKD approval rests on EMPA-KIDNEY, a trial that was notable for enrolling a broader spectrum of CKD than either DAPA-CKD or CREDENCE. It included patients with eGFR as low as 20 mL/min/1.73 m² and did not require heavy proteinuria for entry. Over a median follow-up of about two years, kidney disease progression or cardiovascular death occurred in roughly 13% of the empagliflozin group versus about 17% of the placebo group, a relative risk reduction of about 28%.7PubMed. Empagliflozin in Patients with Chronic Kidney Disease As with the other two drugs, the benefit was consistent whether or not the patient had diabetes.
A long-term follow-up analysis of EMPA-KIDNEY tracked outcomes through both the active treatment period and the time after the trial ended. During the combined period, the risk of kidney disease progression was about 23.5% in the empagliflozin group versus 27% in the placebo group, and cardiovascular death occurred in roughly 3.8% versus 4.9%.8PubMed. Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease The fact that benefits persisted even after the trial period ended suggests the kidney protection is not just a short-term hemodynamic effect that vanishes when you stop the drug.
How These Drugs Actually Protect the Kidneys
You might wonder why a class of drugs designed to lower blood sugar would protect kidneys, especially in people who do not have diabetes. The answer has less to do with glucose control and more to do with how these drugs change the pressure inside the kidney’s filtering units.
Normally, the kidney reabsorbs glucose and sodium together in the proximal tubule. SGLT2 inhibitors block that process, which means more sodium flows downstream to a structure called the macula densa. That signal triggers a feedback loop (tubuloglomerular feedback) that constricts the blood vessel feeding into the glomerulus. The net effect is lower pressure inside the glomerulus, which reduces the physical stress on the kidney’s filters.9Diabetes & Metabolism Journal. Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics10PubMed Central. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
By lowering that intraglomerular pressure, SGLT2 inhibitors also reduce the kidney’s oxygen demand. The kidney’s outer layer, the cortex, is particularly vulnerable to oxygen deprivation in CKD. Modeling studies suggest that the reduction in filtration rate lowers the tubular transport workload, improving oxygenation in that cortex.11PubMed Central. Renal effects of SGLT2 inhibitors: an update This mechanism does not depend on glucose at all, which is why the kidney benefits show up in people without diabetes.
The eGFR Dip That Worries Patients (but Probably Shouldn’t)
One of the most common sources of anxiety for people starting an SGLT2 inhibitor is the initial drop in eGFR. Your lab values may show your kidney function got “worse” in the first few weeks. This can be alarming enough to make some patients stop the drug, and some physicians hesitate to prescribe it. But the dip appears to be a hemodynamic effect of reducing that intraglomerular pressure, not actual kidney damage.
A retrospective study of CKD patients starting SGLT2 inhibitors found that those who had a greater than 10% initial dip in eGFR actually had better long-term kidney outcomes. Their odds of rapid kidney function decline were substantially lower compared to patients whose eGFR barely changed at the start.12Journal of Pharmaceutical Health Care and Sciences. Association between initial eGFR dip and renal function trajectory in patients with chronic kidney disease initiating SGLT2 inhibitors: a retrospective cohort study In other words, the dip is a sign that the drug is doing its job. If you see your eGFR drop early on and your doctor tells you to keep going, that is usually the right call.
Beyond Diabetic Kidney Disease: IgA Nephropathy and Other Causes
The fact that dapagliflozin and empagliflozin are approved for CKD broadly, not just diabetic kidney disease, has opened the door for their use in a range of kidney conditions. One area attracting particular attention is IgA nephropathy, the most common type of primary glomerulonephritis worldwide.
A study of SGLT2 inhibitor use in IgA nephropathy patients found a significant reduction in proteinuria: about 23% at three months and 27% at six months. That antiproteinuric effect held across different age groups, baseline kidney function levels, and regardless of whether patients were also on immunosuppressive drugs or had diabetes.13PubMed Central. Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy Case reports of non-diabetic IgA nephropathy patients who had persistent proteinuria despite standard treatment with blood pressure medications showed that dapagliflozin brought proteinuria down to subnephrotic levels within months.14Revista Colombiana de NefrologÃa. Clinical findings of iSGLT-2 use in non-diabetic IgA nephropathy patients: A case series This matters because proteinuria itself drives progressive kidney damage in IgA nephropathy, so reducing it can slow the disease independently of other treatments.
Safety Considerations
SGLT2 inhibitors are generally well tolerated, and the major CKD trials did not show higher rates of serious adverse events compared with placebo. But there are some real side effects worth knowing about. The most common is genital yeast infections, which occur because the drug causes excess glucose to be excreted in urine, creating a more hospitable environment for fungal growth. Clinical trials and real-world data consistently show a meaningfully increased risk of genital infections, and meta-analyses suggest a marginal increase in urinary tract infections as well.15PubMed Central. Sodium-glucose co-transporter 2 inhibitors use and the risks of genital and urinary tract infection: What should we know?
A rarer but more serious concern is euglycemic diabetic ketoacidosis, a form of ketoacidosis that occurs without the very high blood sugars that typically signal the condition. This makes it easy to miss. It tends to arise in specific situations: after surgery, during illness, or with prolonged fasting. Most guidelines recommend temporarily stopping the drug a few days before scheduled surgery and during acute illness. For patients without diabetes, the risk is extremely low but not zero.
There was an early concern with canagliflozin about increased amputation risk, which emerged in the CANVAS trial (a cardiovascular outcomes study). CREDENCE, the kidney trial, did not confirm this signal. Neither DAPA-CKD nor EMPA-KIDNEY flagged amputation as a concern. Current thinking is that the signal in CANVAS may have been a statistical fluke or related to a higher-risk population, but it is worth mentioning because it sometimes still deters prescribing.
Combining SGLT2 Inhibitors with Finerenone
Finerenone is a newer drug, a nonsteroidal mineralocorticoid receptor antagonist (MRA), that has its own approval for slowing CKD progression in diabetic kidney disease. A natural question is whether combining it with an SGLT2 inhibitor gives you more benefit than either alone. Early evidence suggests the answer is yes.
A retrospective analysis of patients with CKD and albuminuria found that the combination of an SGLT2 inhibitor and finerenone produced a greater reduction in albuminuria than either drug used alone. The combination was well tolerated, and there was an additional practical advantage: SGLT2 inhibitors appeared to offset the risk of high potassium levels (hyperkalemia) that finerenone can cause on its own.16PubMed Central. Real-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in Chronic Kidney Disease This synergy makes biological sense because the two drug classes protect the kidney through different pathways: SGLT2 inhibitors reduce intraglomerular pressure, while finerenone dampens inflammatory and fibrotic signaling.17PubMed Central. Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease Prospective trials testing this combination over the long term are still needed, but many nephrologists are already using both together in higher-risk patients.
Sotagliflozin and the Next Wave
Sotagliflozin is a dual inhibitor: it blocks both SGLT2 (in the kidney) and SGLT1 (mainly in the gut). It is currently approved for heart failure and carries a cardiovascular indication, but it does not yet have a standalone CKD approval. That said, kidney-specific data from the SCORED trial are encouraging. A secondary analysis found that sotagliflozin reduced the risk of a composite kidney endpoint (sustained 50% eGFR decline, eGFR below 15, dialysis, or transplant) by about 38% compared with placebo in people with type 2 diabetes and CKD.18PubMed Central. Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial
A systematic review and meta-analysis of sotagliflozin’s renal effects across multiple trials showed a modest eGFR decline of about 1.2 mL/min/1.73 m² per year in longer studies, with no significant change in urinary albumin excretion.19PubMed. Effect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials Whether sotagliflozin’s dual mechanism offers a meaningful advantage over pure SGLT2 inhibitors for kidney protection is still an open question. SCORED was cut short due to loss of funding during the COVID-19 pandemic, which limited the kidney data that could be collected. For now, sotagliflozin is one to watch but not one with a CKD label on the bottle.
Why So Many Eligible Patients Are Not on These Drugs
Despite strong trial evidence and guideline endorsement, SGLT2 inhibitor prescribing in CKD remains surprisingly low. One real-world study found that among patients with high-risk diabetic kidney disease who were eligible for an SGLT2 inhibitor, only about a third were actually receiving one. Older age and recent hospitalization were associated with lower rates of prescribing, while higher body weight and a history of heart failure made prescribing more likely.20PubMed Central. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
A qualitative study exploring barriers in clinical practice identified several themes. Clinicians varied widely in their comfort level prescribing these drugs, particularly primary care doctors who saw CKD management as the nephrologist’s territory. Patients worried about adding another pill and about side effects like genital infections. Reimbursement and insurance coverage were a persistent obstacle. On the flip side, endorsement by national guidelines and peer influence among clinicians were strong facilitators for adoption.21PubMed Central. Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research If you have CKD and are not on an SGLT2 inhibitor, it is worth asking your nephrologist or primary care doctor whether you are a candidate. The gap between the evidence and real-world use remains one of the bigger missed opportunities in kidney care.
Cost-Effectiveness Across Health Systems
SGLT2 inhibitors are not cheap, and cost is one of the barriers to wider use. But health-economic analyses generally find them cost-effective when you factor in the downstream savings from fewer dialysis starts, fewer hospitalizations, and longer life. A Thai analysis found that adding an SGLT2 inhibitor to standard care for people with type 2 diabetes and CKD increased life expectancy by roughly half a year and improved quality-adjusted life years, while also generating potential cost savings by reducing the need for dialysis and kidney transplantation.22PubMed Central. A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand
A Japanese analysis reached a similar conclusion in both diabetic and non-diabetic CKD populations, finding SGLT2 inhibitors well below that country’s standard willingness-to-pay threshold for a quality-adjusted life year.23PubMed Central. Cost-Effectiveness Analysis of SGLT2 Inhibitors for Cardio-Renal-Metabolic Disease Based on Data from Japanese Studies The economic case is strongest for patients at highest risk of progressing to dialysis, because dialysis itself is extraordinarily expensive. For health systems struggling to cover these drugs upfront, the math tends to work in the drug’s favor over a few years.
An Unexpected Bonus: Effects on Anemia
One of the more surprising secondary effects of SGLT2 inhibitors is an increase in hemoglobin levels. Anemia is extremely common in CKD, and managing it usually requires erythropoiesis-stimulating agents or iron supplementation. Early clinical trials noticed that patients on SGLT2 inhibitors had rising hemoglobin and hematocrit levels, an effect initially attributed to the drugs’ mild diuretic action concentrating the blood. But the increase in hemoglobin, on the order of 0.5 to 0.7 g/dL, exceeded what volume contraction alone would explain and did not track well with the timing of fluid loss.
Subsequent research found that SGLT2 inhibitors stimulate erythropoietin production and improve iron metabolism, even in patients with reduced kidney function. Treatment with these drugs reduced the prevalence of anemia and the risk of developing it in patients with diabetes, heart failure, or CKD.24NefrologÃa (English Edition). Effect of SGLT2 inhibitors on anemia and their possible clinical implications This is not a primary reason to prescribe an SGLT2 inhibitor, but for a CKD patient already dealing with anemia, it is a welcome side benefit that may reduce the need for other medications.